Privacy Policy
Signals Blog

Contributors

Categories

Update from the Clinic: April

. Welcome to your Update from the Clinic for the month of April. Athersys provides disappointing interim results for its MultiStem® cell therapy in ulcerative colitis patients. Sernova continues to demonstrate safety and biocompatability of its Cell Pouch technology...

Data is king

> I’m not an academic, but I’ve been to many scientific conferences and read many more papers over the past 10 years or so. I know how important data is in research. I also know how important it is in communications (where visits, likes or shares are...

Regenerative Medicine Deal Review: April

. Welcome to your RM deal review for the month of April. There were two notable acquisitions this past month. NeoStem entered into an agreement to acquire California Stem Cell, while Aastrom acquired Sanofi’s regenerative medicine business. Read on to find out more....

Right Turn: What is aging?

> I said goodbye to a much beloved uncle this week. I suppose it’s inevitable that mortality, aging and how and when we share our feelings with those we love would be on my mind over the 16 hours of driving to and from the funeral. Also not surprising that...

Right Turn: The evolution of medicine

. May is the month that students learn whether they’ve been accepted into medical programs at Canadian universities. Good luck kids! Good luck parents! This infographic, on the evolution of medicine, comes courtesy of BestMedicalDegrees.com, an independent online...

Cell Therapy Commercialization: Look for Headroom

. Of all the formidable challenges that a biotechnology company will stumble upon in its quest to commercialize, perhaps there is none more frustrating than a failure to get a product reimbursed by payers. After years of navigating the gauntlet of risk that is...

Subscribe to Signals

Subscribe to our blog list to receive the latest news and updates.

You have Successfully Subscribed!